2.30
+0.04(+1.77%)
Currency In USD
Address
6707 Winchester Circle
Boulder, CO 80301
United States of America
Phone
720 307 2892
Sector
Healthcare
Industry
Biotechnology
Employees
46
First IPO Date
N/A
| Name | Title | Pay | Year Born |
| Dr. Nicholas A. Saccomano Ph.D. | President, Chief Executive Officer & Director | 741,743 | 1959 |
| Mr. Jason A. Leverone CPA | Chief Financial Officer | 565,258 | 1974 |
| Dr. Samuel Agresta M.D., M.P.H. | Chief Medical Officer | 650,371 | 1973 |
| Dr. James Blake Ph.D. | Senior Vice President of Computational Drug Discovery | 0 | N/A |
| Dr. Dylan Hartley Ph.D. | Chief Scientific Officer | 0 | 1969 |
| Mr. Rogan P. Nunn J.D. | General Counsel & Secretary | 0 | N/A |
| Dr. Kevin S. Litwiler Ph.D. | Senior Vice President of DMPK & Clinical Pharmacology | 0 | N/A |
| Dr. Mark L. Boys Ph.D. | Senior Vice President of Discovery Chemistry | 0 | N/A |
| Ms. Roberta Alton | Senior Vice President of Clinical Operations | 0 | N/A |
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.